Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07502560 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

Name: A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland — clinical trial record (NCT07502560)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorGlaxoSmithKline

Started2026-03-31

View on ClinicalTrials.gov ↗

The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland. Participants will be enrolled and randomized in a 3:1 ratio to receive either recombinant zoster vaccine or placebo.

Amendment history 2 changes detected by DataLookout

2026-05-13

Recruitment opened

2026-05-13

Trial sites expanded: 0 → 8 locations

Trial Details

NCT Number	NCT07502560
Lead Sponsor	GlaxoSmithKline Collaborators: Finnish Vaccine Research;, Dr Arto Palmu
Conditions	Herpes Zoster
Enrollment	33,609 participants
Start Date	2026-03-31
Primary Completion	2030-04-01 (estimated)
Study Completion	2037-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-12